Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 35.07 CNY -3.55% Market Closed
Market Cap: 6.2B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chengdu Easton Biopharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Income from Continuing Operations
ÂĄ226.6m
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
ÂĄ3B
CAGR 3-Years
16%
CAGR 5-Years
19%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
ÂĄ4.5B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
226.6m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Income from Continuing Operations amounts to 226.6m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
11%

Over the last year, the Income from Continuing Operations growth was -8%. The average annual Income from Continuing Operations growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been 8% over the past three years , 11% over the past five years .

Back to Top